OBJECTIVE： To evaluate efficacy and safety of Jinghua weikang capsules combined with triple therapy in the treatment of Helicobacter pylori （Hp） related chronic gastritis or peptic ulcer，and to provide evidenle-based reference in clinic. METHODS： Retrieved from Medline， PubMed， Embase， ISI Web of Science， CNKI and Wanfang database， RCTs about Jinghua weikang capsules combined with triple therapy versus traditional triple therapy or quadruple therapy which combined with bismuth in the treatment of Hp related chronic gastritis or peptic ulcer were collected. After literature screening and data extraction， the quality of literatures were evaluated by using modified Jadad scale. Meta-analysis was performed by using Rev Man 5.0 statistical software. RESULTS： A total of 22 RCTs were included， including 3 069 patients. Results of Meta-analysis showed that compared with triple therapy group， Jinghua weikang capsules combined with triple therapy group was better in Hp eradication rate [OR＝1.96，95％CI（1.47，2.60），P＜0.001] and remission rate of digestive tract symptoms [OR＝1.75，95％CI（1.27，2.41），P＜0.001]， with statistical significance； but there was no statistical significance in the incidence of ADR in 2 groups [OR＝0.67，95％CI（0.36，1.25），P＝0.21]. There was no statistical significance in Hp eradication rate [OR＝0.97，95％CI（0.75，1.26），P＝0.83] and remission rate of digestive tract symptoms [OR＝1.37，95％CI（0.97，1.94），P＝0.07] in Jinghua weikang capsules combined with triple therapy group and quadruple therapy group， but the incidence of ADR in Jinghua weikang capsules combined with triple therapy group was lower than quadruple therapy group， with statistical significance [OR＝0.25，95％CI（0.15，0.44），P＜0.001]. CONCLUSIONS： Compred with triple therapy，Jinghua weikang capsules combined with triple therapy can improve the rates of Hp eradication and digestive tract symptom remission. Compared with quadruple therapy， it can reduce the incidence of ADR.